Biosimilar
Biocon inks pact with Janssen to commercialise biosimilar products in Japan
Biocon Biologics on Thursday said it has inked a pact with Janssen for launching a biosimilar medication for the treatment of autoimmune diseases in Europe, the United Kingdom, Canada, and Japan. The company, a subsidiary of Biocon Ltd, has inked a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson. This agreement clears the way to commercialise its Bmab 1200, a proposed biosimilar to Stelara. As per the terms of the settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan, the company said in a statement. Regulatory filings in these markets are currently under review, it added. Biocon Biologics had earlier announced a settlement agreement in the US for Bmab 1200 launch no later than February 22, 2025, once approved by the USFDA. The US health regulator has accepted the company's Biologics License Application (BLA) for Bmab 1200 for ...
 "Biocon inks pact with Janssen to commercialise biosimilar products in Japan")
We continue to increase our reach and access in India, say Sun Pharma execs
Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more
 "We continue to increase our reach and access in India, say Sun Pharma execs")
Biocon in talks with Mylan to merge biosimilar businesses: Report
Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said
 "Biocon in talks with Mylan to merge biosimilar businesses: Report")
Biosimilar market on the growth path as top drugs double in size
Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled
 "Biosimilar market on the growth path as top drugs double in size")
Biosimilar launches in emerging markets, research key drivers for Biocon
Weak sentiments, rich valuations will weigh on the scrip in near term
 "Biosimilar launches in emerging markets, research key drivers for Biocon")
Pharma companies increase investments for global biosimilar push
Biosimilars are made from living cells and are far more complex and expensive to manufacture than generic drugs
 "Pharma companies increase investments for global biosimilar push")
